Business Context and Reporting Period
This Form 6-K/A filing by GlaxoSmithKline plc (GSK) covers the period ending January 2015, with the report dated January 28, 2015. The filing serves as a Director Declaration in conformity with Listing Rule 9.6.14.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory notification regarding board appointments and does not contain financial statements or performance data.
Material Changes
No material financial changes are reported. The filing discloses a corporate governance change: Ms. Lynn Elsenhans, a Non-Executive Director of GSK, was appointed as a Director to the Board of Flowserve Corporation on September 8, 2014.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The document is limited to the disclosure of the director appointment.
Key Facts for Investor Verification
- Ms. Lynn Elsenhans holds a directorship at Flowserve Corporation as of September 8, 2014.
- This filing is a compliance notification under Listing Rule 9.6.14 and does not include financial results.
- Investors should refer to GSK's Form 20-F or quarterly reports for financial performance data.